The week in health tech, explained in plain English.Get the free newsletter →
October 31, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

CMS Finalizes Tougher Oversight of Organ Procurement Groups

CMS finalized a rule on Oct. 30 that tightens federal oversight of organ procurement organizations, the nonprofits responsible for recovering organs for transplant across the country. According to Becker's Hospital Review, the rule clarifies when the agency can decertify poor performers and allows top-performing OPOs to compete for multiple donation service areas. CMS first proposed the rule in January.

The measure takes effect 60 days after its Nov. 3 Federal Register publication. In practice, that means weaker OPOs face a clearer path to losing their federal designation, while high performers gain room to expand the territories they serve.

The move continues a multiyear federal push to hold OPOs accountable for measurable results, after years of criticism that inconsistent performance has left viable organs unrecovered. For hospitals and transplant programs, the shift could reshape which organizations manage donation in their regions and raise pressure on OPOs to hit benchmarks or risk replacement.

More in Government

Government

Medicare Rule Could Cut Remote Patient Monitoring Access

A proposed CMS rule could sharply reduce Medicare reimbursement for remote patient monitoring, threatening access for rural and chronically ill patients.

Why it matters: Remote monitoring has become a fast-growing, loosely overseen Medicare service, and changing how it pays could reshape home-based care for millions.

Government

HHS Launches National Plan to Overhaul US Kidney Care

HHS launched a national kidney care plan centered on prevention, dialysis reform with more patient choice, and overhauling the transplant system.

Why it matters: Kidney disease affects 1 in 7 US adults and drives major Medicare spending, so federal direction here reshapes care models and markets.

Government

FDA Approves First Once-Weekly Insulin for Children

The FDA approved Novo Nordisk's Awiqli, the first once-weekly basal insulin for children 10 and older with Type 2 diabetes.

Why it matters: Weekly rather than daily insulin could improve adherence for a growing number of children with Type 2 diabetes.